Robert Baze­more makes Hutchmed deal his grand fi­nale as Epizyme CEO; Black Di­a­mond reshuf­fles the deck with de­par­tures of CMO, CSO

→ One minute, Epizyme CEO Robert Baze­more helped en­gi­neer a part­ner­ship with Hutchmed on de­vel­op­ing Tazverik in Chi­na. The next minute, he gave his job to some­one else.

Baze­more stepped aside as Epizyme’s chief ex­ec­u­tive the same day the biotech an­nounced the deal, ced­ing the throne to Grant Bogle, the chief com­mer­cial of­fi­cer at Tesaro from 2015 un­til 2019 — the year Glax­o­SmithK­line’s takeover of the on­col­o­gy-fo­cused com­pa­ny was com­plet­ed. Since 2019, Bogle has kept a seat on Epizyme’s board of di­rec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER